|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
WednesdayCopaxone, which features less frequent dosing, will be approved in the United States in the near future.
Copaxone (Glatiramer Acetate), which features less frequent dosing, will be approved in the United States in the near future.
Analysts believe it is critically important for Teva to get patients switched to the three-times-weekly drug before competition from cheap generic versions of Copaxone hit the market as soon as this year. READ MORE |